The JUPITER Results: Will The Planets Align For OTC Statins?
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca's JUPITER trial onCrestor (rosuvastatin) greatly expands the pool of patients who may benefit from statin use, which could help make the case for an OTC switch in the cholesterol-lowering class in the future
You may also be interested in...
Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch
Switching statins OTC will require comprehensive consumer education to enable self-selection and flexibility from FDA on the types of information it considers product labeling
Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch
Switching statins OTC will require comprehensive consumer education to enable self-selection and flexibility from FDA on the types of information it considers product labeling
Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch
Switching statins OTC will require comprehensive consumer education to enable self-selection and flexibility from FDA on the types of information it considers product labeling